Why this poison is interesting

This page exists because of what it can be compared against. Organophosphates and carbamates inhibit the same enzyme, at the same serine, producing the same transmitter accumulation at the same three receptor populations. Two things differ, and both should make carbamate poisoning the easier illness: there is no bioactivation step, so nothing is manufactured after absorption; and the inhibited enzyme reverses by itself, so there is no aging, no expiry on the antidote, and no permanent lesion to outlast the poison.

That is a genuine natural experiment in human toxicology, and it has been run. Lamb and colleagues prospectively studied 1288 patients self-poisoned with carbamate insecticides across six Sri Lankan hospitals, with plasma concentrations measured to confirm which compound had been taken. 183 (14.2%) required intubation and ventilation and 71 (5.5%) died, and the authors conclude that carbamate poisoning did not appear to be much less toxic than poisoning with some liquid organophosphate formulations they had studied in the same hospitals.¹

The reversibility is real, and it does show up in the data: no patient in the cohort showed delayed onset of toxicity akin to the intermediate syndrome seen after organophosphate poisoning.¹ So the chemistry is not wrong. It is simply answering a different question from the one clinicians ask of it. A lesion that will undo itself in hours still has to be survived for those hours, and the thing that kills is the airway, not the durability of the enzyme complex.

A poison is a drug whose kinetics have escaped its pharmacology.

The toxic principle

Acetylcholinesterase hydrolyses acetylcholine through a serine in its active site, and the enzyme's whole utility depends on the serine being freed again within microseconds. Both insecticide classes attack that step; they differ only in what they leave attached to it.

An organophosphate leaves a phosphoryl group, which water removes so slowly that the enzyme is effectively destroyed — and which can then lose an alkyl group and become permanently unrescuable. A carbamate leaves a carbamoyl group. That group is also removed by hydrolysis, and also far more slowly than an acetyl group — but fast enough to matter clinically, and it cannot age, because there is no alkyl group on a carbamoyl carbon to lose in the way there is on a phosphorus.

Two further consequences follow from the same chemistry, and both are practical. First, an oxime has no established role: its purpose is to attack a phosphorylated enzyme that will not otherwise recover, and against a complex that recovers by itself it is a solution to a problem that is already solving. Second, the assays behave differently. A blood sample from a carbamate-poisoned patient continues to decarbamylate in the tube Inferred, so a cholinesterase measured late or handled slowly can read closer to normal than the patient is.

Toxicokinetics

The striking feature of this table is how much of it is empty by comparison with the organophosphate page. Several rows there describe processes that determine the illness — bioactivation, fat storage, aging — and here they simply do not exist.

Carbamates — the organophosphate table with the two decisive rows removed
Parameter	Therapeutic	In overdose	Why it changes
Absorption	Rapid by ingestion, inhalation and across skin	Onset is faster than with a thion organophosphate, because nothing has to be made first	The first row where the two classes separate. The compound that reaches the synapse is the compound that was swallowed, so the peak effect tracks absorption rather than hepatic metabolism.
Bioactivation	None required. The carbamate is the active inhibitor	None	The organophosphate page's central kinetic argument — that manufacture of the toxic species continues after absorption is complete — has no counterpart here. Nothing is being made downstream of the gut.
Formulation	Marketed as powders and as concentrated liquids	Concentration and formulation drove outcome in the cohort more than which carbamate was taken¹	The clinical presentation and cause of death did not differ markedly between the three carbamates studied, while case fatality varied with the strength and formulation of the product.¹ The vehicle and the concentration are toxicologically part of the poison, exactly as they are for liquid organophosphate formulations.
Distribution	Distributes to cholinergic synapses throughout the body; some members cross the blood–brain barrier readily	Central effects prominent with the more lipophilic members	The class spans a wide range of central penetration, which is the same axis that separates physostigmine from neostigmine among the therapeutic carbamates. The bedside consequence is how much of the syndrome is central, and it varies by compound rather than by dose alone.
The lesion	—	Carbamylated acetylcholinesterase, hydrolysing back spontaneously over minutes to hours	This is the row the whole page turns on. The lesion has a half-life of its own that is independent of clearance, of dose and of any treatment given — and it is short enough that recovery of enzyme activity does not have to wait for protein synthesis.
Aging	—	Does not occur	There is no dealkylation reaction available to a carbamoylated enzyme, so there is no chemical clock, no expiry on the antidote and no permanently inactivated pool. This removes the single feature that makes organophosphate poisoning irreversible, and it does not make the illness safe.
Elimination	Hepatic hydrolysis and oxidation; urinary excretion of metabolites	Rapid relative to the lipophilic organophosphates	Both the poison and the lesion resolve on their own schedules and both are short. The duration of the illness is set by the airway and by the ventilator, which in survivors of the cohort meant a median of 67.8 hours of intubation.¹
Dialysability	—	Never assessed. EXTRIP has published no recommendation covering carbamates³	An absence that is genuinely uninformative rather than an open question. A lesion that reverses spontaneously within hours is not a plausible target for extracorporeal removal, and the class has never been proposed as one.

Metabolism and the metabolites

There is no toxic metabolite. The interesting metabolism on this page is the metabolism of the enzyme–poison complex itself, which is the only reaction in this library where the body's route back to health is the spontaneous hydrolysis of a covalent bond it did not intend to make.

Carbamylation and its spontaneous reversal — a lesion with an end point built in

Carbamate insecticideActive as supplied. No P450 step, no oxon, nothing manufactured
Carbamylated acetylcholinesteraseCatalytically dead. The same functional lesion as a phosphorylated enzyme
Spontaneous hydrolysis — decarbamylationActive enzyme restoredThe route back, requiring no antidote and no new protein synthesis
The reaction that is not availableAging — does not occurNo alkyl group is lost, so no permanently unrescuable complex forms
Acetylcholine accumulates at muscarinic, nicotinic and central synapsesIdentical to organophosphate poisoning while it lasts — and it is this, not the enzyme chemistry, that kills
Recovery as enzyme is freedHours rather than the days-to-weeks of organophosphate poisoning¹ — and no intermediate syndrome follows¹

Elimination and accumulation

Nothing accumulates. That sentence carries most of the difference between this page and the organophosphate page, and it is worth being precise about what it means: there is no fat depot releasing compound over days, no manufactured metabolite outlasting its parent, and no pool of permanently inhibited enzyme awaiting replacement by synthesis.

One genuine reassurance does survive the data, and it is worth stating because it changes what happens after the acute phase. No patient in the 1288-patient cohort showed delayed onset of toxicity akin to the intermediate syndrome, and the median time to death was similar across all three carbamates studied — carbofuran 42.3 h (IQR 5.5–67.3), carbosulfan 21.3 h (11.5–71.3), fenobucarb 25.3 h (17.3–72.1), p = 0.99.¹ Deterioration happens early or not at all. A carbamate-poisoned patient who has recovered has recovered, which is precisely what cannot be said after an organophosphate.

Target organs — and why those

The target organs are the organophosphate page's target organs, for the same receptor-type reasons, with two differences: the timescale is shorter, and there is no late neuromuscular lesion. The cards below state only what differs; the shared mechanism is set out in full on that page.

Airway and bronchial mucosa

TargetMuscarinic receptors on glands and bronchial smooth muscle

Why hereIdentical to organophosphate poisoning — simultaneous secretion and bronchoconstriction, and the one target atropine reaches. It is also the proximate cause of death in a poisoning that would otherwise resolve by itself, which is the whole argument of this page. Established

At the bedsideBronchorrhoea, wheeze and the full muscarinic set. Atropine is titrated against the chest, exactly as it is after an organophosphate.

Neuromuscular junction and diaphragm

TargetNicotinic receptors on skeletal muscle

Why hereAcetylcholine accumulation fasciculates and then depolarising-blocks the junction, and atropine cannot reach it. What is absent is the second lesion: no patient among 1288 developed anything resembling the intermediate syndrome.¹ The acute weakness resolves as the enzyme decarbamylates rather than as new enzyme is synthesised. Established

At the bedsideFasciculation, weakness and respiratory failure — 14.2% of the cohort were intubated, for a median of 67.8 hours in survivors.¹ Recovery, when it comes, does not have a relapse behind it.

Central nervous system

TargetCentral cholinergic synapses

Why hereCentral penetration varies widely across the class, so the prominence of coma and seizures is compound-dependent rather than simply dose-dependent. Reduced GCS at presentation was associated with worse outcome in the cohort — though the authors also note that some carbosulfan patients died after presenting with a normal GCS.¹ Inferred

At the bedsideAgitation, coma, seizures, and centrally mediated respiratory depression. A normal conscious level on arrival is not a safe discharge criterion.¹

Heart

TargetMuscarinic receptors at the sinoatrial and atrioventricular nodes

Why hereVagal slowing, offset unpredictably by ganglionic stimulation and by hypoxia — the same ambiguity as after an organophosphate, and the same trap. The heart rate is not a measure of how atropinised the patient is. Established

At the bedsideBradycardia or tachycardia. Titrating atropine to a heart rate rather than to the chest under-treats the patient in either direction.

Timeline of effects

Carbamates — the same crisis, compressed, with nothing after it

Time

What you seeWhat is happening

MinutesOnset
What you seeMiosis, salivation, bronchorrhoea, vomiting, sweating, fasciculation, weakness, agitation or coma.
What is happeningNo bioactivation step, so effect follows absorption directly. Onset is faster than with a thion organophosphate and there is no lag while the liver manufactures the inhibitor.
First hoursPeak cholinergic crisis
What you seeRespiratory failure in those who develop it — 14.2% of 1288 patients required intubation.¹ Some who died had presented with a normal GCS.¹
What is happeningMaximal enzyme inhibition. Clinically indistinguishable from organophosphate poisoning at this point; the classes separate afterwards, not here.
HoursSpontaneous decarbamylation
What you seeImprovement in secretions, pupils and strength, without any specific treatment having been given for the enzyme.
What is happeningThe carbamoyl group hydrolyses off. Enzyme activity returns without protein synthesis and without an oxime — the reaction that is not available after an organophosphate.
Up to ~3 daysVentilated recovery
What you seeMedian duration of intubation in survivors 67.8 h (IQR 27.5–118.8)¹ — considerably longer than the enzyme chemistry alone predicts.
What is happeningAspiration, hypoxic injury, sedation, and — with the liquid concentrate formulations rather than the powders — the hydrocarbon solvent, all outlast the enzyme lesion. The ventilator is treating the consequences of the crisis, not the crisis.
After recoveryNo second act
What you seeNo delayed weakness. No patient in the cohort showed delayed toxicity akin to the intermediate syndrome.¹
What is happeningThere is no aged enzyme pool to replace and no fat depot to empty. This is the phase where the chemistry's promise is actually kept, and it is the only one where it is.

What the mechanism predicts at the bedside

Treat it exactly like an organophosphate at the front door. Airway, atropine titrated to the chest, ventilation if the diaphragm fails. The classes are indistinguishable during the phase that kills.
Do not reason from reversibility to reassurance. 14.2% intubated and 5.5% dead in 1288 patients¹ is what the reversible lesion produced.
A normal GCS on arrival is not a safe discharge criterion — some patients in the cohort died having presented with one.¹
An oxime has no established role, because the enzyme reactivates without one. This page makes no claim that an oxime is harmful in carbamate poisoning; it claims there is nothing for it to do.
A cholinesterase level can under-call the poisoning, because decarbamylation continues in the sample after it is taken. The clinical state is the more reliable measure here than it is after an organophosphate.
Ask about the formulation and the concentration, not only the compound. Case fatality in the cohort varied with the strength and formulation of the product while the clinical presentation did not differ markedly between carbamates.¹
Expect deterioration early or not at all. Median time to death was similar across all three carbamates and there is no intermediate syndrome to wait for.¹
A patient who has recovered has recovered — which is exactly what cannot be said after an organophosphate, and is the one genuine piece of reassurance the chemistry earns.
Extracorporeal removal has never been assessed³ and there is no mechanistic case for it against a lesion that reverses in hours.

The antidote, from the poison's side

There is one antidote and it is the same one, doing the same job, with the same limitation: atropine blocks the muscarinic receptor and cannot reach the neuromuscular junction. What is different is the absence of the second antidote, and the absence is principled rather than an evidence gap.

Atropine: Competitive muscarinic antagonism, titrated to a dry chest. It does not touch the enzyme, does not shorten the poisoning, and is the intervention that keeps the airway usable while the carbamoyl group hydrolyses off by itself. Established
Pralidoxime and the oximes: No established role, and for a different reason than on the organophosphate page. There the trial evidence shows no clinical benefit and a trend towards harm at the WHO doses²; here the target is already resolving. An oxime exists to rescue an enzyme that will not recover unaided, and a carbamylated enzyme recovers unaided. This page states an absence of indication, not a demonstrated harm.
Ventilation: The treatment that determines outcome, and the one that is not an antidote. Median duration in survivors of the cohort was 67.8 hours.¹
Benzodiazepines: For seizures, on the ordinary grounds. No neuroprotective claim is made here.
Extracorporeal removal: Never assessed. EXTRIP has published no recommendation covering carbamates.³

Critical appraisal

The traditional-teaching badge is carried by one citation for the doubt, and it is a strong one but it is one. Lamb and colleagues studied 1288 patients and concluded carbamate poisoning did not appear to be much less toxic than poisoning with some liquid organophosphate formulations in the same hospitals.¹ What is downgraded is the inference from reversible chemistry to benign illness, not the reversibility, which the same paper's absence of any intermediate syndrome supports.
The cohort's exposures are not UK exposures. Concentrated agricultural carbamate formulations taken deliberately are not the same event as a domestic or occupational exposure, and the case-fatality figures on this page should not be transported to a different population. They are printed because they contest a mechanistic inference, not as a UK risk estimate.
The comparison with organophosphate case fatality is the authors' own and is made across their own consecutive cohorts¹, not within a randomised comparison. It is quoted as they framed it — as an argument about agricultural policy and product substitution — and no page in this library ranks poisons by danger.
The three-leaving-groups argument is inference, badged as such. It is a reconstruction from enzyme chemistry that explains the clinical difference between the classes economically, and no source on this page measures the half-life of a carbamoylated enzyme in a poisoned human.
The claim that decarbamylation continues in the sample tube is standard laboratory practice reasoning and is not sourced here. It is stated as a caution about interpreting a low-normal result, not as a quantified artefact.
No lethal dose and no minimum lethal dose appears on this page, and no compound is described as more or less dangerous than another. The formulation-and-concentration finding is reported because it separates the vehicle from the molecule, which is a mechanistic point.
The absence of an oxime indication is an argument from mechanism plus an absence of evidence, and it is deliberately not badged traditional. Downgrading it would require a citation contesting the claim that carbamylated enzyme reactivates spontaneously, and no such citation was found. Not manufacturing a badge is as much a part of this discipline as applying one.
EXTRIP's silence here is uninformative³ and is recorded for consistency with the rest of the library rather than because a recommendation is awaited.

References

1
Lamb T, Selvarajah LR, Mohamed F, et al. High lethality and minimal variation after acute self-poisoning with carbamate insecticides in Sri Lanka — implications for global suicide prevention. Clinical Toxicology 2016 Sep;54(8):624–31. PMID 27252029. (Prospective study of 1288 patients self-poisoned with carbamate insecticides across six Sri Lankan hospitals, with plasma carbamate concentration measured to confirm the compound. 183 (14.2%) intubated and ventilated, 71 (5.5%) died. Median time to death: carbofuran 42.3 h (IQR 5.5–67.3), carbosulfan 21.3 h (11.5–71.3), fenobucarb 25.3 h (17.3–72.1), p = 0.99. Median duration of intubation in survivors 67.8 h (IQR 27.5–118.8). "No patients showed delayed onset of toxicity akin to the intermediate syndrome seen after OP insecticide poisoning." Reduced GCS at presentation associated with worse outcome, though some carbosulfan patients died after presenting with normal GCS. Concludes carbamate poisoning "did not appear to be much less toxic than poisoning with some liquid OP insecticide formulations" studied in the same hospitals.)
2
Buckley NA, Eddleston M, Li Y, et al. Oximes for acute organophosphate pesticide poisoning. Cochrane Database of Systematic Reviews 2011 Feb 16;(2):CD005085. PMID 21328273. (Cited here for the organophosphate comparison only: "Current evidence is insufficient to indicate whether oximes are harmful or beneficial", and the WHO-recommended regimen "is not supported". The review addresses organophosphate poisoning, not carbamate poisoning.)
3
EXTRIP Workgroup — published recommendations index. Extracorporeal Treatments in Poisoning Workgroup. Cited for the absence of any recommendation covering carbamate insecticides. extrip-workgroup.org/recommendations

Carbamate insecticides

At a glance